Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide vs Empagliflozin in T2DM (PIONEER 2)
NCT02863328Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02863328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863328.